1.Different MRI and clinicopathological characteristics between breast cancer susceptibility gene-positive and -negative breast cancer
Mengying YANG ; Shunan CHE ; Shuluan CHEN ; Jing LI
Chinese Journal of Radiology 2025;59(5):532-539
Objective:To investigate the difference of MRI and clinicopathological characteristics between patients with breast cancer susceptibility gene (BRCA)-positive and BRCA-negative breast cancer.Methods:The study was a cross-sectional study. MRI images and clinicopathological data of breast cancer patients with postoperative pathologically confirmed and determined BRCA gene status in Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College from January 2012 to April 2021 were retrospectively analyzed. A total of 120 BRCA-positive patients with 122 lesions and 120 BRCA-negative patients with 126 lesions were enrolled. All patients underwent MRI examinations, including pre-contrast and post-contrast scans. The breast MRI features of the patients were analyzed, including internal necrosis, lesion depth, degree of background parenchymal enhancement (BPE), type of lesion, shape and margin of the mass lesion, internal enhancement, and edema. Clinicopathological analysis included family history, molecular subtype, nuclear grade, and the status of human epidermal growth factor 2 (HER-2), estrogen receptor (ER), and progesterone receptor (PR). The χ2 test and Fisher exact test were performed to determine the differences in MRI features and clinicopathological manifestations of BRCA-positive and BRCA-negative breast cancers. Significant features obtained by univariate analysis were included in the multivariate logistic regression analyses to select independent influencing factors for predicting BRCA mutation in breast cancer. Results:Statistically significant differences were observed between patients with BRCA-positive and BRCA-negative breast cancers in the following features: family history, molecular subtype, ER or PR-positive status, HER-2-negative status, nuclear grade, BPE, internal necrosis, edema, and the shape and margin of the mass lesion( P?0.05). The multivariate logistic regression analyses showed that HER-2 negativity ( OR=3.277, 95% CI 1.087-9.875, P=0.035), round or oval shape ( OR=2.688,95% CI 1.143-6.320, P=0.023), circumscribed margin ( OR=3.001,95% CI 1.374-6.554, P=0.006), edema ( OR=4.407,95% CI 2.100-9.244, P<0.001), and the minimal or mild degree of BPE ( OR=2.520,95% CI 1.328-4.782, P=0.005) were significant independent factors in predicting BRCA gene mutations. Conclusions:There are differences in MRI features and clinicopathological manifestations of BRCA-positive and BRCA-negative breast cancers. HER-2 status, the shape and margin of lesions, edema and the degree of BPE could independently predict the BRCA status of breast cancer.
2.Different MRI and clinicopathological characteristics between breast cancer susceptibility gene-positive and -negative breast cancer
Mengying YANG ; Shunan CHE ; Shuluan CHEN ; Jing LI
Chinese Journal of Radiology 2025;59(5):532-539
Objective:To investigate the difference of MRI and clinicopathological characteristics between patients with breast cancer susceptibility gene (BRCA)-positive and BRCA-negative breast cancer.Methods:The study was a cross-sectional study. MRI images and clinicopathological data of breast cancer patients with postoperative pathologically confirmed and determined BRCA gene status in Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College from January 2012 to April 2021 were retrospectively analyzed. A total of 120 BRCA-positive patients with 122 lesions and 120 BRCA-negative patients with 126 lesions were enrolled. All patients underwent MRI examinations, including pre-contrast and post-contrast scans. The breast MRI features of the patients were analyzed, including internal necrosis, lesion depth, degree of background parenchymal enhancement (BPE), type of lesion, shape and margin of the mass lesion, internal enhancement, and edema. Clinicopathological analysis included family history, molecular subtype, nuclear grade, and the status of human epidermal growth factor 2 (HER-2), estrogen receptor (ER), and progesterone receptor (PR). The χ2 test and Fisher exact test were performed to determine the differences in MRI features and clinicopathological manifestations of BRCA-positive and BRCA-negative breast cancers. Significant features obtained by univariate analysis were included in the multivariate logistic regression analyses to select independent influencing factors for predicting BRCA mutation in breast cancer. Results:Statistically significant differences were observed between patients with BRCA-positive and BRCA-negative breast cancers in the following features: family history, molecular subtype, ER or PR-positive status, HER-2-negative status, nuclear grade, BPE, internal necrosis, edema, and the shape and margin of the mass lesion( P?0.05). The multivariate logistic regression analyses showed that HER-2 negativity ( OR=3.277, 95% CI 1.087-9.875, P=0.035), round or oval shape ( OR=2.688,95% CI 1.143-6.320, P=0.023), circumscribed margin ( OR=3.001,95% CI 1.374-6.554, P=0.006), edema ( OR=4.407,95% CI 2.100-9.244, P<0.001), and the minimal or mild degree of BPE ( OR=2.520,95% CI 1.328-4.782, P=0.005) were significant independent factors in predicting BRCA gene mutations. Conclusions:There are differences in MRI features and clinicopathological manifestations of BRCA-positive and BRCA-negative breast cancers. HER-2 status, the shape and margin of lesions, edema and the degree of BPE could independently predict the BRCA status of breast cancer.
3. Retrospectively analysis of characteristics and risk factors of immune treatment-related hepatic adverse events in malignant tumor
Shuluan LI ; Xiaoping GAO ; Qianqi CHEN ; Xiaohong FU ; Yan ZHAO ; Jiangman DUAN ; Yueqiang TANG ; Jie SUN ; Junling LI ; Qiming ZHOU
Chinese Journal of Oncology 2020;42(1):50-54
Objective:
To explore the clinical features and risk factors of hepatic injury due to immune checkpoint inhibitors (CPI) therapy in malignant tumor.
Methods:
Data of 112 patients (64 men and 48 women) who received CPI between January 2016 and March 2019 in Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen Hospital, and Huazhong University of Science and Techology Union Shenzhen Hospital were retrospectively collected. The median age of these patients was 60 years.
Results:
Hepatic adverse events were observed in 30 patients out of 112 patients (26.8%). Among them, the incidence of grade 3-5 hepatic adverse events were 7.14% (8/112). The median time of hepatic adverse event occurrence was 3 weeks (2-30) after undergoing therapy. The results of univariate and multivariate analyses showed that liver cancer was attributed to the CPI induced hepatitis (
4.Effect of Yunnan baiyao aerosol treatment in subcutaneous hematoma after percutaneous coronary intervention
Xiaoying CHEN ; Shuluan SUN ; Yuqin LI ; Xiaohua HONG ; Maozhen LIN ; Jinghua XU ; Lixuan HUANG
Chinese Journal of Modern Nursing 2014;20(22):2859-2861
Objective To study the efficacy of Yunnan baiyao aerosol treatment for patients undergone percutaneous coronary intervention ( PCI) with subcutaneous hematoma .Methods Seventy patients undergone PCI with subcutaneous hematoma were chosen as the research objects and divided into the observation group (35 cases) and the control group (35 cases) according to the order of odd or even number of patients enrolled . The patients in the observation group were treated with Yunnan baiyao aerosol plus Yunnan baiyao aerosol insurance solution, and those in the control group were treated with wet dressing of magnesium sulfate (50%). The treatment effects , healing time and degree of pain relief of the two groups were compared .Results The total efficiency of the observation group was 97.1%, which was significantly better than 85.7 of the control group (χ2 =11.893, P<0.05).The healing time of the observation group was (3.6 ±0.8) days, which was significantly shorter than (5.3 ±1.1) days in the control group (t=7.382, P<0.05).After 3 days of the treatment, 4 patients in the observation group and 13 patients in the control group had the severe pain .The difference of the degree of pain relief between the observation group and the control group was statistically significant ( Z =-7.432, P <0.05 ).Conclusions Yunnan baiyao aerosol treatment to subcutaneous hematoma after PCI can rapidly and safely relieve pain , swelling and stasis .It can be operated and accepted by patients easily .And it is worthy of clinical application .
5.The effects of using the Xinhuang Pian application to cure phlebitis after chemotherapy
Jinghua XU ; Shuluan SUN ; Yayan ZENG ; Xingsheng CAI ; Suping YANG ; Youqi CHEN
Chinese Journal of Practical Nursing 2006;0(24):-
Objective To study the effects of using the Xinhuang Pian application to cure phlebitis after chemotherapy, and then make out the proper therapeutic regimen. Methods Divided 130 patients with phlebitis after chemotherapy into the experimental group ( 69 cases) and the control group ( 61 cases) randomly. The Xinhuang Pian application was used in the experimental group, while the routine nursing method was used in the control group. Results The curative ratio in the experimental group and the control group were 92.75% and 32.79% respectively, the significant different was existed between them,P

Result Analysis
Print
Save
E-mail